ARID1A deficiency attenuates the response to EGFR-TKI treatment in lung adenocarcinoma

ARID1A deficiency attenuates the response to EGFR-TKI treatment in lung adenocarcinoma

BackgroundConcurrent genetic alterations (e.g., TP53 comutations) significantly impair EGFR-TKI responsiveness and survival outcomes in EGFR-mutant lung adenocarcinoma (LUAD). AT-rich interactive domain 1A (ARID1A), which is a key subunit of SWI/SNF complexes, demonstrates critical regulatory functi...

Full description

Saved in:
Bibliographic Details
Main Authors: Fangfang Yang, Helei Hou, Guanqun Wang, Guangming Fu, Xingfa Huo, Xueqin Duan, Na Zhou, Xiaochun Zhang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Pharmacology
Subjects:
ARID1A
epidermal growth factor receptor
tyrosine kinase inhibitor
resistance
lung adenocarcinoma
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1582005/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1582005/full

Similar Items